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An inbred hamster model for the human acetyI at ion polymorphism
was used to investigate the biochemical basis for the acetyI at ion
polymorphism and its relationship with the liver cytosolic enzymes
arylamine N-acetyItransferase (NAT), N-hydroxyarylamine 0-acetyl-
transferase (OAT), and arylhydroxamic acid N,0-acyItransferase
(N,O-AT). NAT and OAT activities were examined in liver cytosols
derived from homozygous rapid and homozygous slow acetylator
hamsters, respectively. Partial purification of hepatic NAT
activity indicated the presence of two distinct NAT isozynes in each
acetylator genotype. One isozyme was designated polymorphic
acetyItransferase (PAT); whereas, the other isozyme was termed
monomorphic acetyItransferase (MAT). Kinetic analysis showed that
the acetyI at ion polymorphism is primarily due to structural variants
of the PAT isozyme. Results from this model may be extrapolated to
the human acetyI at ion polymorphism.
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An inbred hamster model for the human acetylation polymorphism
was used to investigate the biochemical basis for the acetylation
polymorphism and its relationship with the liver cytosolic enzymes
arylamine N-acetyltransferase (NAT), N-hydroxyarylamine 0-acetyl-
transferase (OAT), and arylhydroxamic acid N,O-acyltransferase
(N,O-AT). NAT and OAT activities were examined in liver cytosols
derived from homozygous rapid and homozygous slow acetylator
hamsters, respectively. Partial purification of hepatic NAT
activity indicated the presence of two distinct NAT isozymes in each
acetylator genotype. One isozyme was designated polymorphic
acetyltransferase (PAT); whereas, the other isozyme was termed
monomorphic acetyltransferase (MAT). Kinetic analysis showed that
the acetylation polymorphism is primarily due to structural variants
of the PAT isozyme. Results from this model may be extrapolated to
the human acetylation polymorphism.
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The involvement of aromatic amines (aryI amines) in certain types
of human cancer was established in the late nineteenth century
(Rehn, 1895). Aromatic amines were first used as precursors for the
chemical synthesis of dyes and subsequently as antioxidants in the
manufacture of rubber products and lubricating oils (Miller and
Miller, 1983). Aromatic amines were recognized as human
carcinogenic agents when workers exposed to these substances were
found to exhibit a high incidence of urinary bladder cancer (Parkes
and Evans, 1984). Benzidine, beta-naphthyIamine, and
4-aminobiphenyl are examples of aryIamine compounds widely used in
the manufacture of plastic and dyes that have been shown to be
carcinogenic (Case et a I., 1954; Case and Pearson, 1954). In
addition, aryIamine compounds are used in industries that
manufacture or use antioxidants, polymers, and pesticides (Schulte
and Eard, 1988). It is now recognized that occupational exposure is
one of the critical risk factors involved in the development of
neoplasia from environmental chemicals.
Stud i es in drug metaboIi sm and d i spos i t i on i nd i cate that
aryI amines usually induce most tumors in excretory tissues (e.g.,
liver, bladder, and intestine) rather than at sites of
administration. It was also found that aryI amine metabolites are
more carcinogenic than their parent compounds. These findings
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demonstrate that aryIamines require metabolic activation by the
host, into reactive electrophiIic species that readily bind to the
nucleophilic sites of macromolecules (e.g., DNA, RNA, and proteins)
and initiate carcinogenesis in target tissues (Miller and Miller,
1981a, b; Lower, 1982; Dipple et al., 1985). Metabolic activation
and deactivation are recognized as important determining factors
that influence individual susceptibility to aryI amine-induced
care i nogenes i s.
Many different enzymatic reactions are involved in the metabolic
activation/deactivat ion of aryIamines (as shown in Fig. 1). Among
these reactions, N-acetylation, N-deacetylation, N-hydroxylation,
and conjugation with glucuronides and suI fates are the main
contributors to the activation of aryIamines to toxic (carcinogenic)
substances. Conversely, ring hydroxylation produces less toxic
substances (Weber and Hein, 1985; Hein, 1988a). The metabolic
pathway implicated in arylamine activation involves the
biotransformation of aryIamines to their corresponding aryI amides
via cytosolic N-acetyItransferase(s) (NAT) and back to the
corresponding aryIamines by microsomal deacetylase(s). AryIamines
and aryIamides can be further activated by N-hydroxylation to
corresponding N-hydroxyaryIamines and N-hydroxyarylamides
(arylhydroxamic acids) respectively. These proximate carcinogens
can be further metabolized to ultimate carcinogens via
UDP-gIucurony11ransferases, suIfotransferases, deacetyIases, and/or
acetyItransferases (Hein, 1988a).
Fig. 1. Metabolic Pathways Leading to DNA-Adducts











Acetylation is a major metabolic pathway in the
biotransformation of aryI amines and hydrazines. The acetylation
reaction is catalyzed by NAT(s) (EC 2.3.1.5), an enzyme responsible
for the enzymatic transfer of an acetyl group, usually from acetyl
coenzyme A (AcCoA), to molecules that contain a primary amine,
hydroxyl, or hydrazine group (Weber, 1973).
Individual differences in acetylation capacity have long been
associated with drug-induced abnormalities such as peripheral
neuritis, hepatitis, and lupus erythematosus (Weber and Hein,
1985). More recently, N-acetylation has been recognized to play a
modulatory role in the activation/deactivat ion of carcinogenic
aromatic amines (Weber and Hein, 1985; Hein, 1988a). Thus,
acetylation reactions contribute to the cytotoxicity, mutagenicity,
and carcinogenicity of aromatic amines.
The capacity for N-acetylation is inherited as a single
autosomal Mendelian trait of two alleles at a single gene locus
(Weber and Hein, 1985). The genotypes of such inheritance can be
identified as homozygous rapid (RR), heterozygous (Rr), and
homozygous slow (rr) acetylators, according to the rate at which
they acetylate aryIamines and hydrazines. This gene-dose
relationship is referred to as the acetylation polymorphism. Human
epidemiological studies have demonstrated that slow acetylator
individuals are predisposed to aryIamine-induced bladder cancer. An
aryIamine bladder carcinogenic model proposes that slow acetylators
having low levels of hepatic NAT activity do not N-acetylate
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aryI amines very well, leading to transport of reactive
N-hydroxyaryIamines to the urinary bladder lumen where they can be
converted into electrophiIic molecules that bind to DNA (Poirier et
al., 1963; Lower and Bryan, 1973; Lower et al., 1979; Poupko et al.,
1979; Beland et al., 1983). In contrast, rapid acetylator
individuals are more susceptible to colorectal cancer because they
express higher levels of O-acetyltransferase (OAT) activity in
coIonic mucosa which converts N-hydroxyaryI amines into reactive
eiectrophiles that bind to DNA (Flammang et al., 1985; Flammang and
Kadlubar, 1986). These findings indicate a relationship between
genetic variability in acetylation capacity and differences in the
metabolic activation/deactivat ion pathway of arylamine carcinogens
(Weber and Hein, 1985; Hein, 1988a).
Because of the biological significance of genetic variability in
acetylation status and arylamine-induced careinogenesis, it is
important to determine the genetic and biochemical factors that





Human hereditary differences in acetylation of drugs was first
termed the "isoniazid acetylation polymorphism." Individual
differences in isoniazid (INH)-induced toxicity of the nervous
system were observed in patients receiving the drug for the
treatment of tuberculosis. This pharmacogenetic trait, however, is
now known as "acetylation polymorphism" because it relates to the
difference in the capacity of individuals to metabolize numerous
drugs and environmental chemicals that are acetylated in the body
tissues (Fig. 2) (Weber, 1987). Slow acetylator individuals tend to
accumulate high concentrations of INH and other hydrazine and
arylamine drugs which are acetyiated prior to excretion.
Consequently, slow acetylators are often more susceptible to
drug-induced toxicities than rapid acetylators (Weber and He in,
1985). The significance of the acetylation polymorphism in
drug-induced toxicity is best illustrated by the mortality of rapid
and slow acetylator rabbits. When exposed to the same doses of INH
for a specified period of time, rapid acetylators survived while
slow acetylators did not (Hein and Weber, 1984).
Fig. 2. Structures of Representative Drugs and








































AcetyIat ion is a major pathway of drug metabolism involved in
the biotransformation of aromatic amines and hydrazines in the body
(Williams, 1959). Usually, acetylation deactivates these chemicals
into inert by-products that are excreted. In some instances,
acetylation activates the chemicals into highly reactive substances
which can initiate carcinogenesis (Weber, 1987).
The discovery by Lipman (1945) of coenzyme A derivatives, and
their central role in the acetylation of drugs, led the way to the
study of NAT enzymes. NAT is responsible for catalyzing the
N-acetylation of aryIamines and hydrazines. Recent studies on NAT
have revealed the existence of various acetyItransferases in several
mammalian species, including man (Weber and Hein, 1985).
Species and Hereditary Variation
The influence of hereditary factors in drug acetylation was
first identified by Hughes et al. (1955), when studies on the
disposition of INH in humans indicated that some individuals,
treated with ordinary therapeutic doses of INH, had a toxic response
to this drug. In addition, Hughes and co-workers found that
individuals who developed a toxic response to INH also tended to
excrete relatively small amounts of acetylated INH in their urine.
These observations suggested that the extent of acetylation was an
individual characteristic and that toxicity resulted in susceptible
persons because they failed to sufficiently acetylate the drug.
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Later, twin studies (Bonieke and Lisboa, 1957) and family studies
(Evans et a I., 1960) demonstrated that acetylation differences
between individuals are almost exclusively inheritable. Individuals
could be phenotypically identified as either rapid or slow
acetylators. Sunahara et al. (1963) provided evidence that subjects
could be identified into 3 subpopulations (phenotypes) corresponding
to homozygous rapid, heterozygous, and homozygous slow acetylator
genotypes.
Genetic analyses conducted in rabbits (Weber et a I., 1976), mice
(Tannen and Weber 1980), and hamsters (Hein et a I., 1985a) have
documented that acetylator differences are controlled by autosomal
Mendelian inheritance of two alleles at a single gene locus.
The genetically determined acetylator status of an individual
has important pharmacokinetic (Weber and Hein, 1979) and
toxicological significance (Drayer and Reidenberg, 1977). The
frequency of a variety of drug-induced pathological conditions has
been shown to be dependent on acetylator status (Bernstein and
Lorincze, 1981; Weber, 1987). Susceptibility to aryIamine-induced
cancers has also been associated with acetylation polymorphism
(Hein, 1988a).
Acetylator Status and Drug Response
Neurotoxicity. INH-induced neurotoxicity was the first drug
toxicity disorder to be associated with the human acetylator
status. Slow acetylators appeared to be more susceptible to
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INH-induced neurotoxicity than rapid acetyiators. Devadatta and
co-workers (1960) reported that INH-induced peripheral neuropathy,
associated with chronic ingest ion of INH, occurred more frequently
in slow acetyiators than in rapid acetyiators. These studies also
demonstrated that the occurrence of this toxicity was related to the
total dose of INH ingested.
No human epidemiological studies of the relationship between
acetyiator status and acute neurotoxicity have been reported.
Several animal studies, however, suggest that hydrazine-induced
neurotoxicity may be influenced by acetyiator status (O'Brien et
al., 1964; Hein and Weber, 1984). The relationship between
drug-induced neurotoxicity and acetyiator status was demonstrated by
studies conducted in rapid and slow acetyiator rabbits. Both rabbit
populations received a similar daily injection of INH over the same
period of time. All slow acetyiator rabbits died of neurotoxicity,
while rapid acetyiator rabbits survived (Hein and Weber, 1984).
Drug-Induced Systemic Lupus Erythematosus. Numerous drugs are
capable of producing systemic lupus erythematosus (SLE). The most
important of these are aromatic amines such as procainamide (an
antiarrhythmic agent) and the hydrazines such as hydralazine (an
antihypertensive agent). The signs and symptoms found in patients
with drug-induce SLE are similar to those found in idiopathic lupus
erythematosus. The precise mechanism by which arylamine and
hydrazine drugs produce this disorder is not known. However,
evidence from chemical studies have shown that an N-hydroxylated
metabolite rather than the parent compound may trigger this disorder
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(Freeman et al., 1979; 1981). Hereditary differences in acetylation
capacity appears to be related to the susceptibility of individuals
in developing drug-induced SLE (Weber, 1987; Hein and Weber, 1989).
Several studies (Litwin et al., 1981; MansiIla-Tinoco et al.,
1982) have demonstrated that lupus patients produce antinuclear
auto-antibodies. It was found that patients in which SLE was
drug-induced were predominantly slow rather than rapid acetylators.
This suggests that acetylator status is not only a factor in
aryI amine-induced carcinogenesis but also with several pathological
d i sorders.
Isoniazid-Hepatitis. It was initially proposed that INH was
more hepatotoxic for rapid than slow acetylators because rapid
acetylators are expected to form monoacetyIhydrazine more rapidly
than slow acetylators. MonoacetyIhydrazine could then be converted
to potent reactive electrophiles that bind covalently to hepatic
macromolecules causing hepatic necrosis (Mitchell et a I., 1975).
This hypothesis has been challenged by more complete INH
pharmacokinetic studies (Timbrell et a I., 1977) that examined the
percentages of metabolites formed and excreted after INH ingest ion.
The data confirmed that higher amounts of acetyl-INH are excreted in
rapid acetylators than in slow acetylators. As expected, the amount
of monoacetyIhydrazine formed was higher in rapid than in slow
acetylators. However, monoacetyIhydrazine can be excreted unchanged
or can be further metabolized in at least 2 ways (Fig. 3): it can be
acetylated to diacetyIhydrazine, a nontoxic metabolite; or it can
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undergo N-hydroxylation through the cytochrome P-450 system to a
highly electrophiIic intermediate. The last pathway is reported to
be responsible for hepatotoxicity; whereas, the first is a
detoxification pathway (MitcheII et al., 1976; Timbrell et al.,
1980). in vivo studies indicated that INH inhibits the acetylation
of monoacetyIhydrazine. These observations have suggested that
after normal therapeutic doses of INH, higher amounts of free INH
remain for longer periods of time in slow acetylators than in rapid
acetylators. Consequently, slow acetylators would have a greater
inhibition of the acetylation reaction (detoxification pathway)
resulting in a greater fraction of monoacetyIhydrazine being
available for the microsomal pathway which leads to hepatotoxicity.
These results indicate that slow acetylators are more susceptible to
drug-induced hepatotoxicity than rapid acetylators.
Acetylator Status and Cancer
Recently, N-acetyI ation has been identified as an important
genetic factor with a modulatory role in the metabolic activation
and deactivation of mutagenic and carcinogenic aryI amines and of
heterocyclic arylamines (Fig. 4) formed during the cooking of beef
and other foods (Weber and Hein, 1985; Hein, 1988a; Sugimura, 1988;
Weber et a I., 1989). Epidemiological studies have shown associa
tions between acetylator status and cancers of the urinary bladder
(Matnoski and Elliot, 1981; Cartwright, 1983), and colon (Lang, et
al., 1986; Mett et a I., 1987).
Fig. 4. Structures of Some Mutagenic Heterocyclic
AryIamines Isolated from Cooked Foods
(Sugimura, 1988). Compounds with asterisks
have been subjected to long-term
carcinogenesis experiments and proved to be
care i nogen i c. IQ, 2-ami no-3-methyIimidazo
[4,5-f] quinoline; MelQ, 2-amino-3,4-
dimethylimidazo [4,5-f] quinoline; MelQx,
2-am i no-3,8-di methyIi m i dazo [4,5-f] qu i no-
xaline; 7,8-DiMelQX, 2-amino-3,7,8- tri-
methylimidazo [4,5-f] quinoxaline; 4,8-
DiMelQX; 2-amino-3,4,8-trimethylimidazo
[4,5-f] qu i noxaI i ne; Trp-P-1, 3-am i no-1,4-
dimethyl-5-H-pyrido [4,3-b]indole; Trp-P-2,
3-am i no-1-methyI-5H-pyri do [4,3-b]i ndoIe;
GIu-P-1, 2-am i no-6-methyId i pyr i do [1,2-a:
3'2'-d]imidazole; A a C, 2-amino-9H-pyrido




































Industrial exposure to arylamine chemicals has been recognized
as a causal agent responsible for the induction of bladder cancer
(Parkes and Evans, 1984). Rehn (1895) was the first to conduct
epidemiological investigations of industrial bladder cancer. He
reported the unusual occurrence of urinary bladder cancer among
fuchsin dye workers. In the 1940's, numerous basic clinical and
epidemiological evidence in humans and animals, indicated that
certain aromatic amines constituted a grave bladder cancer hazard.
Studies by Case and co-workers (Case et a I., 1954; Case and Pearson,
1954) clearly showed an association between bladder cancer deaths
and exposures to certain aryIamines in dye-manufacturing companies.
The fact that carcinogenic aromatic amines are acetylated by the
same enzymes(s) which acetylates INH and other drugs (Glowinski et
a I., 1978) suggested a potential role for the acetylation
polymorphism in individual susceptibility to bladder cancer (Weber,
1978; Lower et aI., 1979). Studies on several populations have
indicated that slow acetylators are more susceptible to
arylamine-induced bladder cancer than rapid acetylators (Cartwright
et al., 1982; Evans et al., 1983; Ladero et al., 1985; Mommsen et
al., 1985; Mommsen and Aagard, 1986). Evans et al. (1983) suggested
that association of slow acetylator status with bladder cancer might
signify that either rapid acetylators are protected because they are
more capable of rendering aromatic amines non-carcinogenic by
N-acetylation, or that slow acetyiators survive longer with bladder
cancer than rapid acetylators. Whether or not acetylator status has
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an appreciable effect on the survival of patients with occupational
bladder cancer requires further investigation.
Although colorectal cancer is the second leading cause of cancer
death in the United States (Lang et al., 1986), the etiology of this
disease is poorly understood. Dietary habits and their effects on
intestinal microflora, bile acids, and fecal bulk are considered to
be the major predisposing factors for this disease (Lang et a I.,
1986). In addition, several aromatic amines identified as pyrolysis
products formed during cooking of food have been shown to induce
intestinal and other tumors in experimental animals (Takayama et
al., 1984a, b).
In recent studies, an association between acetylator status and
colorectal cancer has been documented. Rapid acetylator individuals
may be more susceptible to colorectal cancer than slow acetylators
due to higher levels of N-hydroxyaryI amine OAT activity present in
the colon of rapid acetylators (Lang et al., 1986; Ilett et al.,
1987). OAT catalyzes the metabolic activation of
N-hydroxyaryIamines to electrophiIic intermediates that bind readily
to DNA and initiate colon cancer.
Metabolic Activation of Aryiamine Carcinogens
Aryiamine chemicals require metabolic activation into reactive
electrophiIic species which bind covalently to DNA, forming
derivatized bases which are thought to induce the initiation of
careinogenesis (Miller and Miller, 1981b). The metabolic pathways
indicated in aryI amine-induced careinogenesis are catalyzed by
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various host enzymes. Hypotheses exist which suggest that
individual susceptibility to drug-induced toxicities is determined
by inheritable differences in these enzymes.
Several reviews (Miller and Miller, 1981a, b; Lower, 1982;
Kadlubar and BeIand, 1985; Hein, 1988a) of aryI amine-induced
carcinogenesis have suggested that aryIamine chemicals are
N-acetylated by cytosolic NAT to aryIamides, and deacetylated by
microsomal deacetylases to the parent aryIamines. AryI amines and
aryI amides undergo N-oxidation to N-hydroxyarylamines and
N-hydroxy-N-acetylarylamines, respectively, by cytochrome P-450 and
flavin-containing monooxygenases. Further activation to their
ultimate electrophilic forms occurs via enzymatic conjugation
reactions with acetate, sulfate, or phosphate groups.
AryIamines and N-hydroxyarylamines can be transported as
N-gIucuronide conjugates to target tissues, such as colon and
bladder. Bacterial gIucuronidases in the colon or the mildly acidic
urine conditions in the bladder can regenerate the aryIamine and
N-hydroxyaryIamine forms. The slightly acidic conditions in the
bladder can protonate the N-hydroxy group of N-hydroxyarylamines,
forming electrophiles that bind to bladder DNA. In contrast,
N-hydroxyarylamines in the colon undergo O-acetylation to the
acetoxy ester, which immediately converts into an electrophile that
binds to colon DNA.
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Distribution and Physicochemical Properties of N-AcetvItransferase
(NAT)
NAT is found in several tissues of a number of species. NAT
activity has been detected in several organs including liver, small
intestine, brain, kidney, lung, spleen, test is, thymus, ovary,
salivary glands, and some peripheral blood cells (Weber, 1973).
Mammalian liver NAT has a broad substrate specificity. An ami no
group attached directly to unsaturated rings or by way of a carbonyl
group is an important structural component of reactive compounds.
Purification studies on avian liver have demonstrated that
pigeon NAT is a monomer with a pi of 4.8 and a molecular mass of
32,900 D (Andres et a I., 1983); whereas, chicken NAT has a molecular
mass of 34,000 D (Deguchi et a I., 1988). Liver NAT from homozygous
rapid acetylator rabbits is a monomer with a pi of 5.2 and a
molecular mass of 33,000 D (Andres et a I., 1987; Kabishev and
Patrushev, 1987). The hepatic NAT from rapid (C57BL/6J) and slow
(A/J) acetylator mice has a molecular mass of 31,500 D (Mattano et
al., 1988).
Partial ami no acid sequences have been determined for the
hepatic NAT of rapid rabbit acetylator (Andres et aI., 1987) and the
chicken (Deguchi et a I., 1988). An oligonucleotide probe has been
synthesized and used to screen a lambda gtio cDNA library enabling
the isolation of a cDNA clone encoding chicken liver NAT (Ohsako et
aI., 1988). The sequence of this cDNA consists of 1,320 nucleotides
including a 861-nucIeotide region coding for 287 amino acids.
Comparisons of NAT amino acid sequences in chicken and rabbit livers
revealed approximately 60-80% homology (Ohsako et a I., 1988).
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Multiple Forms of Acetyitransferases and Deacetvlases
Different enzymatic acetyl transfer reactions (as shown in Fig.
5) are involved in the metabolic activation of arylamine carcinogens
and their N-hydroxyarylamine and N-hydroxy-N-acetyIarylamine
(arylhydroxamic acid) derivatives (Hein, 1988a). Recent studies
have suggested that many of these enzymatic pathways are mediated by
one or more enzymes with diverse catalytic activity (Smith and
Hanna, 1986; Mattano et al., 1988; Kato et al., 1988).
Acetyl Coenzyme A-dependent (AcCoA) Arylamine N-Acetyltrans-
ferase (NAT). Enzymatic transfer of the acetyl group from AcCoA to
acceptor aryI amines was first characterized in pigeon liver
preparations by Bessman and Lipmann (1953). Their data suggested
the formation of an acetylated enzyme intermediate via various
co-factors, including AcCoA. Subsequent studies demonstrated that
N-acetylation is a two-step process in which the enzyme oscillates
between a free and an acetylated form (Weber and Hein, 1985). The
reaction is usually written as follows:
AcCoA CoA Acceptor Amine Acetyl Amine
NAT Ac-NAT NAT
The overall reaction can be written
AcCoA NAT—-CoA Ac-NAT
Ac-NAT Amines—►Acetyl-amine NAT




















Studies of pigeon liver (Jacobson, 1961) and rabbit liver (Andres et
al., 1987) NATs have demonstrated that transfer of the acetyl group
from the acetylated enzyme to the acceptor amine is the
rate-limiting step for the N-acetylation of strongly basic amines
(Weber and Hein, 1985).
Arylhydroxamic Acid-Dependent Arylamine N,N-Transacetylase.
N,N-Transacetylase catalyzes the transfer of the acetyl group from
N-hydroxy-N-acetyIarylamine to form an arylamide (Booth, 1966). The
transacetylase activity has been found in many organs (Weber, 1973).
Studies on substrate specificities have indicated that arylamine
carcinogens, such as AF and ABP, serve as acetyl acceptor molecules;
while, arylhydroxamic acids such as N-OH-AAF and N-OH-AABP serve as
acetyl donor molecules. In contrast, AcCoA does not serve as an
acetyl donor molecule for this reaction in rat liver (Booth, 1966).
Based on these results, Booth concluded that N,N-transacetylase
activity was different from the AcCoA-dependent NAT. Recent studies
of rabbit (Glowinski et al., 1980) and hamster (Hein et al. 1986a;
Kato and Yamazoe, 1988) liver cytosols, however, have provided
evidence that support the existence of an enzyme capable of
catalyzing both N,N-transacetylase and AcCoA-dependent NAT
activities. Thus, further research is necessary to determine if
these activities are catalyzed by different enzyme(s) in certain
spec i es.
Arylhydroxamic Acid N.O-Acyltransferase (N,0-AT). N.O-AT is
responsible for the intramolecular N,0-acyI transfer of arylhydrox
amic acids to form electrophiIic intermediates (King, 1974; King
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and Allaben, 1978). The interaction of arylhydroxamic acids and
N.O-AT is outlined in Fig. 6. The arylhydroxamic acid binds to the
active site of the enzyme and acetylates it. The acetylated enzyme
may then acetylate the oxygen atom of the arylhydroxylamine derived
from the arylhydroxamic acid donor. This intramolecular N- to
O-acyI transfer yields a highly reactive acetoxy arylamine
intermediate (Fig. 6, step b) which undergoes heterolytic cleavage
to form an arylnitrenium ion. This ion reacts with tissue
nucleophiles (Fig. 6, step c) such as nucleic acids and proteins,
including the nucleophilic sites (Fig. 6, step d) on N,O-AT (King,
1974; King and Allaben, 1978; Hanna et al., 1982). Inhibition
studies by Smith and Hanna (1988) and Wick et al. (1988) have shown
that bioactivation of arylhydroxamic acids by N.O-AT is accompanied
by irreversible inactivation of arylhydroxamic acid
N,N-transacetyIase activity (Fig. 6, step a).
Evidence supporting the formation of an acetoxy intermediate is
indirect, since the acetoxyarylamine products formed via
arylhydroxamic acid N,O-AT are too unstable to allow their isolation
(Kadlubar and Be Iand, 1985). Product formation, however, is deduced
from the structure of adducts formed when various nucleophiles are
used as trapping agents.
The arylhydroxamic acid N,O-AT is expressed in several species
including rat, hamster, rabbit, and mouse. The derivatives formed
by arylhydroxamic acid N.O-AT can induce tumors in a wide spectrum
Fig. 6. Interaction of N-Arylhydroxamic Acids and

















of tissues such as kidney, mammary gland, and the gastrointestinal
tract (King, 1974; Weber, 1987). Rat liver N,O-AT has been shown to
be responsible for the activation of N-OH-AAF to a mutagen in the
Salmonella typhimurium mutagenesis assay system (King, 1974).
Arylhydroxamic acid N,O-AT has been purified to electrophoretic
homogeneity in rat (AMaben and King, 1984), mouse (Mattano et al.,
1988), rabbit (Glowinski et al., 1980), and hamster (Saito et al.,
1986) liver. It co-purifies with AcCoA-dependent NAT, providing
further evidence for the existence of a common protein capable of
catalyzing several acetyltransferase activities.
Arylhydroxamic Acid-Dependent N-Hvdroxyarylamine N.O-Trans-
acetylase. Bartsch et al. (1972, 1973) were the first to describe
the intermoIecu Iar transfer of the N-acetyl groups of certain
carcinogenic arylhydroxamic acids (e.g., N-OH-AABP and N-OH-AAF) to
the oxygen atom of N-hydroxyaryI amines (e.g., N-OH-ABP and
N-OH-AF). This reaction gives rise to N-acetoxyaryIamine
metabolites, highly unstable derivatives, which are immediately
hydrolyzed into strongly electrophiIic intermediates capable of
binding to the nucieophilie sites of cellular macromolecules.
Bartsch and co-workers (1972) demonstrated that AcCoA did not
serve as an acetyl donor for the N,O-transacetylase activity,
whereas N-OH-AABP and N-OH-AAF are the most efficient acetyl
donors. These observations suggested that N,O-transacetylase
activity differed from the AcCoA-dependent NAT activity.
Arylhydroxamic acid N,O-transacetylase activity has many
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similarities with arylhydroxamic acid N,N-transacetylase activity
described by Booth (1966).
The N,O-transacetylase activity has been identified in various
species (e.g., rat, rabbit, and hamster) and it is expressed in
several tissues. Bartsch and co-workers (1972) observed 6-fold
variability between rabbit livers for N,O-transacetylase and
suggested that the variation might be related to the NAT hereditary
poIymorph i sm.
Acetyl Coenzvme A-Dependent N-Hydroxvarylamine O-Acetyltrans-
ferase (OAT). It was postulated that a major pathway leading to the
formation of arylamine-DNA adducts involves the N-acetylation of the
N-hydroxyarylamine to an N-hydroxy-N-acetylarylamine followed by the
formation of an N-acetoxyaryIamine via an intramolecular
N,0-acyI transfer (King, 1974). The N-acetoxy derivatives then bind
covalently with DNA, forming derivatized bases which are thought to
initiate the neoplastic process. However, studies have demonstrated
that the formation of arylamine-DNA adducts usually involves the
N-oxidation of primary aryI amines to N-hydroxy derivatives, followed
by direct O-acetylation of the oxygen atom by AcCoA-dependent
N-hydroxyarylamine OAT (BeIand and Kadlubar, 1985; Flammang and
Kadlubar, 1986).
AcCoA-dependent N-hydroxyarylamine OAT activity has co-purified
with NAT activity in hamster liver (Saito et a I., 1986) and mouse
liver (Mattano et a I., 1989). In addition, genetic co-regulation
has been shown in hamster liver between OAT and NAT activities (Hein
et a I., 1987a) and has been suggested to occur in human liver
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(Flammang et a I., 1987), colon (Flammang et aI., 1988) and bladder
(KirI in et al., 1989).
Arylamide Deacetylase. The acetyl group of arylacetamides
(e.g., AAF and AABP) is removed by microsomal deacetylases. This
activity has been reported in the hepatic and extrahepatic tissues
of several mammalian species (Hein, 1988a).
Initial studies with guinea pig, a species with low
N-hydroxylation activity (Gutmann and Bell, 1977), provided evidence
that deacetylation can lead to the formation of mutagenic products
from AAF. In addition, Aune et al. (1985) indicated that the
pathway which activates AAF to mutagenic products included
deacetylation followed by monooxygenation catalyzed by cytochrome
P-450.
No correlation between acetylator status and microsomal
deacetylase has been detected in several species (reviewed in Hein,
1988a). However, a study by Hultin and Weber (1987) reported
differences in microsomal AAF deacetylase activity between rapid and
slow acetylator mice.
Arylhydroxamic Acid Deacetylase. Deacetylation of arylhydrox-
amic acids (e.g., N-OH-AAF) to N-hydroxyarylamines (e.g., N-OH-AF)
has been proposed as one of the critical metabolic steps in the
formation of hepatic DNA adducts and the initiation of liver tumors
in mouse (Lai et al., 1988). Furthermore, microsomal deacetylase
activity has been implicated in the metabolic activation of N-OH-AAF
to electrophilic species mutagenic in bacterial tester systems
(Schut et aI., 1978).
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Acetylation Polymorphism in the Inbred Hamster
Genetic animal models, which exhibit biochemical and
physiological properties similar to the human trait, are used to
assess the significance of hereditary factors affecting drug
toxicity and carcinogenesis (Weber and Hein, 1985). Although
investigating human traits in animal models is an indirect approach,
animal studies facilitate the acquisition of information about the
human condition under circumstances that may be impossible to
simulate in humans due to ethical constraints or methodological
difficulties.
Unlike rabbit and mouse, the hamster has high levels of
acetyItransferase activities, as well as relatively high levels of
deacetylase activities in liver. The ability to readily measure
acetylase and deacetylase activities in hamster tissues makes it a
unique model for investigating the role of acetylator genotype on
the following: the expression of acetyItransferases and
deacetyIases; drug-induced toxicities; and aryI amine-induced
care i nogenes i s.
An acetylator gene-dose relationship towards hepatic NAT
activity in slow and rapid acetylator Syrian inbred hamsters has
been demonstrated (Hein et al., 1985a). NAT polymorphic expression
has also been shown in blood lysates, intestine, kidney, lung,
bladder, and colon (Hein et al., 1986b; 1987b, c; Ogolla et al.,
1988). In each tissue, highest levels of activity are found in
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homozygous rapid acetylators, lowest levels in homozygous slow
acetylators, and intermediate levels in heterozygous acetylator
progeny.
Upon partial purification by an ion-exchange chromatography (Hein
et al., 1985b; 1987a), two distinct acetyltransferase proteins have
been identified in both rapid and slow acetylator hamster liver
cytosol. One isozyme exhibited catalytic activity levels that are
acetylator genotype-dependent (NAT activity levels differ according
to acetylator genotype) and is referred to as the polymorphic
acetyltransferase (PAT) isozyme. In contrast, the other isozyme
exhibited catalytic levels that are acetylator genotype-independent
(NAT activity levels are similar across acetylator genotype). This
isozyme is referred to as the monomorphic acetyltransferase (MAT)
i sozyme.
Multiple forms of acetyltransferase activity have been
identified (Hein et al., 1985b; Smith and Hanna, 1986). Hein and
co-workers (1985b) identified the liver N-OH-AAF/AAB
N,N-transacetylase activity in rapid and slow acetylator hamsters.
The N,N-transacetylase activity exhibited an acetylator
genotype-independent expression. Also, multiple forms of
acetyltransferase activity have been demonstrated by Smith and Hanna
(1986), who were able to separate hepatic N-OH-AAF N,O-AT and PABA
NAT activities by affinity chromatography. It was further shown
that sulfamethazine NAT activity and N-OH-AAF N,O-AT activity are
both inactivated by N-hydroxyphenacetin. In addition, Smith and
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Hanna (1986) found that neither of these activities is protected by
cysteine, a low molecular weight nucleophile, but it does protect
PABA NAT activity. Consequently, it was proposed that
suIfamethazine NAT and N-OH-AAF N,O-AT activities are associated
with a single enzyme protein; while, PABA NAT activity is not
associated with N-OH-AAF N.O-AT activity.
Rationale for this Study
Inherited differences in acetyItransferase activities are
thought to play an important role in the metabolic activation and/or
deactivation of aromatic amine carcinogens. Two genetically variant
forms of N-acety I transferases (PAT and MAT) have been identified in
hamster liver. However, the relationship between the PAT and MAT
isozymes, as well as their role in the metabolic activation of
aromatic amines is not well understood.
Genetic and biochemical characterization of the isozymes is
needed in order to elucidate the biochemical factors affecting the
mechanism(s) responsible for the activation of carcinogenic aromatic
amines. It is expected that determination of the factors involved
in the activation of arylamine and N-hydroxyarylamine carcinogens
will enhance the understanding of the biochemical and molecular
mechanisms associated with the biotransformation of aryIamines, as
we 11 as N-hydroxyaryI am i nes.
This study was designed to purify the acetyItransferase activity
responsible for the N-acetyI at ion polymorphism in the inbred
hamster. The main objective of this investigation was to determine
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the role and contribution of the PAT and NAT isozymes in the
metabolism of aromatic amine carcinogens.
Research Aims
The specific aims of this investigation are to:
1. Partially purify the PAT and MAT isozymes from homozygous
rap i d and homozygous sIow acetyIator hamster Ii vers.
2. Determine the expression of multiple forms of
acetyItransferase isozymes.
3. Perform kinetic characterization studies on the isozymes.
4. Purify the PAT and MAT isozymes from homozygous rapid
acetyiator hamsters to apparent homogeneity.
5. Determine the relationship between acetyiator status and




Reagent grade PABA potassium salt, DMAB, dithioerythritol, DTT,
INH, ABP, S-AcCoA synthetase (EC 6.2.1.1), EDTA, PMSF, and ATP were
purchased from Sigma Chemical Co., St. Louis, MO; AcCoA lithium salt
was obtained from Pharmacia LKB, Inc. Piscataway, NJ; [^H]acetate
(sp. act. 4.5 Ci/mmole) was obtained from Dupont, New England
Nuclear Co., Boston, MA; AF and [ring 3H] N-OH-AF (112 mCi/mmole);
were purchased from Chemsyn Laboratories, Lexena, KS; [ring ^H]
N-OH-ABP (141 mCi/mmole); and [ring 3H] N-OH-DMABP (166 mCi/mmole)
were donated by Drs. Fred Kadlubar and Thomas Flammang at the
National Center for Toxicological Research, Jefferson, AR.
Animals
Bio. 87.20 homozygous rapid acetylator Syrian inbred hamsters
were obtained from Bio. Breeders, Watertown, MA. Bio. 82.73/H
homozygous slow acetylator Syrian inbred hamsters were originally
derived from the Bio-Research Institute, Cambridge, MA but have
since been maintained in the animal care facilities of The Morehouse
School of Medicine for several generations. The two inbred strains
have been described elsewhere (Altman and Katz, 1979) and




Preparation of Tissue Cytosol
Hamsters were sacrificed by decapitation after a preliminary
carbon dioxide anesthesia. The livers were removed rapidly,
washed, minced, and homogenized (25% w/v) in ice-cold 20 mM
potassium phosphate buffer (pH 7.4), containing 1 mM DTT, 1 mM EDTA,
and 50 uM PMSF, using a motor driven homogenizer (Biospec Products,
BartlesviIle, OK). The homogenate was subjected to sequential
centrifugation at 10,000 x g for 20 min followed by 105,000 x g for
60 min. The final supernatant (cytosol) was assayed for protein and
enzymatic activity, or further purified as described below. All
enzyme isolation and purification steps were performed at 4°C.
An ion-Exchange FPLC of Hamster Liver Cytosol
Separat i on of hamster Ii ver cytosoI NAT act i v i t i es was
accomplished by an ion-exchange method using a Fast Protein Liquid
Chromatography (FPLC) system. Fifteen mg of Bio. 87.20 or Bio.
82.73/H liver cytosol protein was applied to a Mono Q HR 5/5
anion-exchange column (Pharmacia LKB, Inc., Piscataway, NJ) that had
been equilibrated with filtered and degassed 20 mM potassium
phosphate buffer (pH 7.4), containing 1 mM DTT and 1 mM EDTA (start
buffer). The column was eluted with filtered and degassed 20 mM
potassium phosphate buffer (pH 7.4), containing 1 mM DTT, 1 mM EDTA,
and 1 M KCI (elution buffer), using a Pharmacia FPLC system (model
GP-250) at a flow rate of 1.0 ml/min and a linear gradient (60 ml)
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from 0-400 mM KCI with an isocratic step at 120 mM KCI. This step
gradient was designed to optimize the separation of the two NAT
isozymes. All buffers and fractions collected were kept ice-cold.
One ml fractions were collected and tested for protein and enzymatic
activity as described in the following determinations.
PABA NAT Activity Determinations
AcCoA-dependent PABA NAT activities were determined in liver
cytosol and chromatographic fractions as previously described (Hein
et a I., 1982b). The procedure measures the AcCoA-dependent
disappearance of arylamine substrate as reflected by decreasing
Schiff's base formation with DMAB. To 50 ul of suitably diluted
enzyme, 20 ul of 1 mM arylamine substrate was added. The reaction
was started with the addition of 20 ul of 4.5 mM AcCoA except in
crude cytosol where 20 ul of 10 mM AcCoA was added. Initial
concentrations in the reaction mixture were 0.22 mM PABA and 1.00 mM
AcCoA except in crude cytosol where 2.22 mM AcCoA was used. The
reaction was terminated by the addition of 50 ul of trichloroacetic
acid (10% w/v) at specified time points to give linear time-activity
plots. After centrifugation in a Brinkmann Eppendorf centrifuge
5414, color development was achieved with the addition of 1 ml of
DMAB solution (equal volumes of DMAB in ethanol (1% w/v) and 1 M
sodium acetate HCI buffer, pH 1.4). After final mixing and
recentrifugation, the tubes were allowed to stand for at least 30
min at room temperature. Absorbance was measured at 460 nm against
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an ethanol blank in a Perkin Elmer Lambda 3A spectrophotometer. The
amount of acetylated product formed was determined by subtracting
the experimental from the control absorbance readings. Controls
received 20 uI of water instead of 20 ul AcCoA. All assays were
performed in duplicate at 37°C. The assay was calibrated by
constructing a standard curve of known PABA concentrations versus
absorbance.
INH NAT Activity Determinations
AcCoA-dependent INH NAT activities were determined in crude
cytosol and in chromatographic fractions by a modification of the
method of Weber (1971) as previously described (Hein et aI.,
1982a). The assay measures the AcCoA-dependent formation of
acetyl-INH. To 50 ul of suitably diluted enzyme, 20 ul of 50 mM INH
was added. The reaction was started with the addition of 20 ul of
4.5 mM AcCoA except in crude cytosol where 20 ul of 10 mM AcCoA was
added. Initial concentrations in the reaction mixture were 11.1 mM
INH and 1.00 mM AcCoA except in crude cytosol where 2.22 mM AcCoA
was used. The reaction was stopped at specified time points by the
addition of 50 ul trichloroacetic acid (10% w/v) to give
linear-activity plots. After centrifugation in a Brinkmann
Eppendorf centrifuge 5414, 1 ml of 0.8 M potassium borate buffer, pH
9.0, was added. The mixture was vortexed and then recentrifuged.
Absorbance was measured at 303 nm versus a water blank in a Perk in
Elmer Lambda 3A spectrophotometer. The amount of acetylated product
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formed was determined by subtracting the control from the
experimental absorbance reading. Controls received 20 uI of water
instead of 20 ul AcCoA. All assays were performed in duplicate at
37°C.
AF and ABP NAT Activity Determinations
AcCoA-dependent AF and ABP NAT activities in crude cytosol and
in chromatographic fractions were determined by a modification of
the method of Andres et a I. (1985) as previously described (Hein et
a I., 1987a). The procedure measures AcCoA-dependent formation of
radio labeled arylamide product. To 60 ul of suitably diluted enzyme
preincubated at 37°C, 20 ul of 450 mM Tris buffer (pH 8.0),
containing 4.5 mM EDTA, 22.5 mM MgC!2, 4.5 mM dithioerythritol, 5 mM
AcCoA, 22.5 mM ATP, 1.5 U/ml S-AcCoA synthetase (EC 6.2.1.1), and
2.25 mM [3H]acetate (sp. act. 4.5 Ci/mmole), was added. The
reaction was started with the addition of 20 ul of 2.5 mM arylamine
substrate (in 25% DMSO). Initial concentrations in the reaction
mixture were 0.5 mM for arylamine substrate and 1.0 mM for AcCoA.
The reaction was terminated at multiple time points by the addition
of 20 ul of a mixture of 5 N NaOH/100 mM sodium acetate to hydrolyze
any remaining [3H]AcCoA to [3H]acetate. The recovery of
[3H]arylamide was readily accomplished by a single extraction with
chloroform. After the chloroform extract was washed twice with
water, an aliquot of the organic layer was transferred to mini
scintillation vials, evaporated to dryness, redissolved in 300 ul of
36
DMSO, and counted with a Beckman LS5801 scintillation counter after
the addition of scintillation cocktail (Liquiscint; National
Diagnostics, Menville, NJ). Controls received 20 uI of 25% DMSO
rather than the arylamine substrate. All assays were performed in
dupIi cate, and enzyme act i v i ty was caIcuIated as prev i ousIy
described (Andres et aI., 1985).
AcCoA-Dependent N-Hydroxyarylamine OAT Activity Determinations
This assay measures the extent to which ring-labeled
N-hydroxyarylamines (e.g., N-OH-AF, N-OH-ABP, and N-OH-DMABP) are
incorporated into DNA adducts as a consequence of the production of
reactive N-acetoxyaryIamines by AcCoA-dependent 0-acetylation. The
procedure was conducted as previously described (Flammang et a I.,
1985). The assays were performed in argon-saturated 20 mM potassium
phosphate buffer (pH 7.4) containing 1 mM DTT, 1 mM EDTA, calf
thymus DNA (2 mg/ml), and tissue cytosol protein (0.5 mg/ml) or
chromotographic fractions as enzyme source. The initial [3H]
N-hydroxyarylamine and AcCoA concentrations were 100 uM and 2 mM
respectively. The control reactions did not contain AcCoA.
Incubations were performed at 37°C for up to 15 min and terminated
by adding 1 ml of ice cold water-saturated N-butanol. One ml of
potassium phosphate buffer (pH 7.4), containing 1 mM DTT and 1 mM
EDTA, was added to the samples. The samples were frozen for 1 h to
separate the aqueous from the organic layer. The N-butanol was
removed and the aqueous layer was washed twice with 1 ml of
N-butanol, followed by two washes with 1 ml of Tris-washed phenol.
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The final aqueous solution was made 100 mM NaCI by adding 100 ul of
1 M NaCI. The samples were placed on ice and the DNA was
precipitated by layering with 5 ml of ice-cold ethanol. The
precipitated DNA was isolated and redissolved with 1 ml of 5 mM
Tris, 10 mM MgCI2 buffer pH 7.0. An aliquot of this solution was
transferred to scintillation vials and counted in a Beckman LS5801
counter to measure the extent of covalent binding to DNA. The
amount of DNA in the aliquot was determined by a colorimetric assay
with diphenyiamine as previously described (Shatkin, 1969). Results
are expressed as nmoles bound/15 min/mg DNA/mg protein.
Purification of PAT and MAT Isozymes
The protocol for the purification of PAT and MAT isozymes from
homozygous rapid acetylator hamsters is summarized in Fig. 7. A
detailed discussion of each purification step is given below.
All purification steps were conducted at 4°C. The following
buffers were used: buffer I (20 mM potassium phosphate, pH 7.4, 1
mM DTT, 1 mM EDTA, 50 uM PMSF, and 10% glycerol), buffer II (same as
buffer I without PMSF), and buffer III (same as buffer I except for
the addition of 1 M KCI).
Fig. 7 Summary of Purification Procedure.
PURIFICATION OF POLYMORPHIC AND MONOMORPHIC N-ACETYLTRANSFERASES
Crude Cytosol (Bio. 87.20)
Sequential Centrifugation
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Step 1. Q-Sepharose Fast Flow Anion-Exchange Chromatography.
Crude cytosol (2.7 g) from Bio. 87.20 Syrian inbred hamster liver
was filtered and applied to a Q-Sepharose anion-exchange column (2.6
x 70 cm) previously equilibrated with 2-3 bed volumes of buffer I
until the protein concentration in the effluent was less than 50
ug/ml (approximately 10-15 h). The column was eluted at a flow rate
of 2 ml/min by a linear salt gradient (900 ml, 0-400 mM KCI) in
buffer III. This gradient separated the PAT and MAT isozymes. Ten
ml fractions were collected and tested for enzymatic activity as
described above. Fractions containing maximum PAT and MAT
activities were pooled, separately. These two enzymatic fractions
were then concentrated by ultrafiItration (Amicon Centriprep
concentrators membrane cutoff 10 KD).
Step 2. Sephacryl S-200 Chromatography. The enzyme solution,
usually 60-200 mg (PAT or MAT), was applied to a Sephacryl S-200
column (1.6 x 70 cm) previously equilibrated with buffer II. The
enzyme was eluted at a flow rate of 1 ml/min. Seven ml fractions
were collected. Fractions containing maximum NAT activities (PAT or
MAT) were pooled.
Step 3. An ion-Exchange FPLC Chromatography. Pooled fractions
(PAT or MAT) from the previous step (approximately 5-10 mg of
protein) were applied to a Mono Q HR 5/5 an ion-exchange column that
had been equilibrated with filtered and degassed buffer II. The
column was eluted at a flow rate of 1.0 ml/min with filtered and
degassed buffer III using a Pharmacia FPLC system as previously
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described. For further details, see An ion-Exchange FPLC of Hamster
Liver Cytosol.
Effects of Temperature on Polymorphic NAT and OAT Activities
Heat inactivation studies were performed with partially purified
Sephacryl S-200 PAT and MAT liver preparations, as well as in the
homogenous PAT liver preparation. A sample from each preparation
was placed in a test tube and incubated in a water bath at 55°C.
Aliquots were then removed at different time intervals and assayed
for PABA NAT, AF NAT, and N-OH-AF OAT activities, as previously
descr i bed.
Protein Determinations
Total protein concentration was determined in 105,000 x g crude
cytosol and chromatographic fractions by the method of Bradford
(1976).
DNA Determinations
The concentration of the recovered DNA from acetyItransferase
binding assays was determined by a coIorimetric assay with
diphenyI amine (Shatkin, 1969).
Apparent Km and Vmax Determinations
MichaeIis-Menten kinetic constants of NAT activity were
determined in liver cytosols as well as with the PAT and MAT
isozymes obtained from three or more homozygous rapid and slow
acetylator hamsters. NAT assays were done in duplicate using
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various concentrations of substrate in the presence of a fixed
saturating concentration of AcCoA. PABA concentrations ranged from
50-500 uM in rapid acetyiators and from 50-2250 uM in slow
acetylators. INH concentrations ranged from 111-11,100 uM and AF
and ABP concentrations ranged from 5-1000 uM in both acetylator
genotypes. The kinetic constants for AcCoA were determined with
AcCoA concentrations ranging from 100-2220 uM in both acetylator
genotypes in the presence of 0.44 mM PABA in crude cytosol, while
the PAT and MAT isozymes of both acetylator genotypes were assayed
in the presence of 0.22 mM PABA.
Apparent Km and Vmax values were calculated for each liver
cytoso I and for the PAT and MAT i sozymes by ENZFITTER non-1 i near
regression data analysis (Leatherbarrow, 1987) and Eadie-Hofstee
linear regression analysis (Dixon and Webb, 1979).
Polyacrylamide Slab Gel Electrophoresis
Polyacrylamide gel electrophoresis (PAGE) of proteins catalyzing
NAT/OAT activity was carried out in an Ephortec (Saddle Brook, NJ)
vertical slab system. Native gels were prepared by the method of
Laemmli (1970), using a Tris-glycine buffer system, pH 8.8. Protein
samples (1-5 ug) were analyzed using either 10 or 12.5%
polyacrylamide resolving gels and 3% stacking gels. A maximum of 20
ul of protein samples were applied onto the stacking gel.
Electrophoresis was performed for 4 h at a constant current of 50
mi 11iamps/slab gel. The temperature was 14°C. Gels were sliced
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vertically with a scalpel. One vertical gel strip was subjected to
silver stain (Merrill et al., 1981) to detect the protein band(s).
The remaining vertical gel strips were cut into segments of 1-2 mm.
Each segment was homogenized in 20 mM potassium phosphate buffer (pH
7.4), containing 1 mM DTT, 1 mM EDTA, and 50 uM PMSF. After
centrifugation in a Brinkman Eppendorf centrifuge 5414, each segment
was assayed for PABA NAT activity as described previously.
SDS-Polyacrylamide Gel Electrophoresis and Molecular Weight
Determi nat i on
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) was performed by the method of Laemmli (1970) using the
Tris-glycine buffer system, pH 8.8, containing 0.1% SDS. The gels
were prepared as described above (see Polyacrylamide Slab Gel
Electrophoresis) with the addition of 0.125% SDS. Protein samples
(100 ul) were mixed with 10 ul of sample buffer [30 mM Tris pH 6.8,
20% SDS, 99% glycerol, 1% bromophenol, 8 M urea and water (0.1
ml/0.2 ml/4 ml/1 ml/0.5 ml/4 ml)]. The samples were denatured by
heating at 95°C for 3 min and reduced by adding 10 ul of
B-mercaptoethanol. One to 5 ug of the reduced and denatured protein
was applied onto the stacking gel in a maximum of 20 ul and
electrophoresed as described for Polyacrylamide Slab Gel
Electrophoresis. Protein bands were detected by silver stain
(Merrill et a I., 1981). Pictures of the gels were taken for
permanent records.
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Approximate molecular weights were determined by comparison of
protein migration to relative mobilities of Enprotech mid range
molecular weight standards (Hyde Park, MA) on silver stained gels
(Merrill et a I., 1981). The markers used were a mixture of proteins
(cytochrome C (12,400 D); IactogIobuIin (18,400 D); carbonic
anhydrase (29,000 D); ova I bum in (43,000 D); glutamate dehydrogenase
(55,000 D); and phosphorylase B (95,500 D)). Additionally, in some
studies Pharmacia low molecular weight standards (Piscataway, NJ)
were used to determine the relative mass of PAT. The molecular
weight markers included a -lactalbumin (14,400 D); trypsin
inhibitor (20,100 D); carbonic anhydrase (30,000 D); ovaI bumin
(43,000 D); albumin (67,000 D); and phosphorylase B (94,000 D).
Data Analysis
Initial reaction rates were determined in individual hamster
cytosolic preparations. The rates were averaged and tested for
significant differences between rapid and slow acetylator genotypes
with a two-tailed Student's t-test.
Apparent Km and Vmax kinetic constants, determined for
individual hamster cytosolic and isozyme NAT activities, were
averaged and tested for significant differences between homozygous
rapid and slow acetylator genotypes with a two-tailed Student's
t-test. Comparisons of Km and Vmax values between PAT and MAT
isozymes, from both rapid and slow acetylators, were assessed by
one-way analysis of variance to test for kinetic differences. The
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levels of significant difference were statistically analyzed by the
Newman-Keuls multiple range test.
Comparisons of rate constants and heated/control ratios,
determined for the PAT and MAT isozymes, were assessed by one-way
analysis of variance to test for rate differences. The levels of
significant difference were statistically analyzed by the
Newman-Keuls multiple range test.
Purified protein samples were desalted in deionized double
distilled water using an Amicon Centriprep concentrator. The
samples were taken to the Microchemical Facility at Emory University
(Atlanta, GA) for protein sequencing, where the desalted protein was
lyophilized and dissolved in 70% formic acid. After lyophiIization,
the protein was dissolved in a mixture of 25% trifluoroacetic
acid/20% acetonitrile (1/1). The protein samples were lyophilized
again and redissolved in 70% acetonitrile in diluted trifluoroacetic
acid. Automatic Edman degradation of the protein was conducted in a




Liver NAT Activity in Inbred Hamsters of Known Acetviator Genotype
Initial rates of AcCoA-dependent NAT activity were determined in
liver cytosols towards PABA, INH, AF, and ABP. Comparisons were
made between homozygous rapid acetylators (Bio. 87.20) and
homozygous slow acetylators (Bio. 82.73/H). A gene dose-response
relationship was expressed in hamster liver cytosol towards PABA,
AF, and ABP; whereas, acetylator genotype-independent expression of
NAT activity was found in hamster liver cytosol towards INH (Table
1).
Liver OAT Activity in Inbred Hamsters of Known Acetviator Genotype
AcCoA-dependent N-hydroxyarylamine OAT activity was determined
in cytosolic liver preparations from homozygous rapid acetylators
and homozygous slow acetylators. The expression of acetylator
genotype in the metabolic activation of N-hydroxyaryIamines was
substrate dependent. Table 2 shows the initial rates of
AcCoA-dependent OAT activity towards N-OH-AF exhibited an acetylator
gene-dose response in hamster liver cytosol. In contrast, the
AcCoA-dependent metabolic activation of N-OH-ABP and N-OH-DMABP
expressed activity levels that did not differ significantly across
acetylator genotypes (Table 2).
45
Table 1. AcCoA-Dependent NAT Activity in Inbred Hamster Liver Cytosol.
Substrates
Acetylator Genotype PABA AF ABP INH
RR 164.9 + 5.0* 51.9 + 5.9* 41.3 + 11.2* 12.0 + 3.0
rr 1.8 + 0.6 8.4 + 1.2 9.1+ 2.0 15.5 + 2.4
Results expressed as nmoles/min/mg protein.
Table values represent Mean + S.D. for four or more animals.
NAT activity in RR acetylator genotype is significantly higher (P < 0.0001) than rr
acetylator genotype.
Table 2. AcCoA-Dependent Metabolic Activation of N-Hydroxyarylamines
by Inbred Hamster Liver Cytosol.
Substrate
Acetylator Genotype N-OH-AF N-OH-ABP N-OH-DMABP
RR 5.8 +1.0* 8.2 + 2.1 3.4 + 0.8
rr 1.2 +0.4 8.2 + 2.1 3.1 + 1.4
Results expressed as nmoles bound/15 min/mg DNA/mg protein.
Table values represent Mean + S.D. for four animals.
Tfetabolic activation in RR acetylator genotype is significantly
higher (P < 0.001) than rr acetylator genotype.
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ResuIts of Part i a 11y Pur i f i ed Acety11ransferase Isozymes in Li ver
Cytosol
Liver cytosols from homozygous rapid and homozygous slow
acetylator hamsters were partially purified by an ion-exchange FPLC.
Two forms of AcCoA-dependent acetyItransferase isozymes were
identified in both rapid and slow acetylator hamsters. The isozymes
have been designated as PAT (acetyiator-genotype dependent) and MAT
(acetyiator-genotype independent) eluting at 60 mM and 120 mM KCI
respectively (Fig. 8). The N-acetylation of PABA (Fig. 8) and AF
(Fig. 9) and the metabolic activation of N-OH-AF (Fig. 10), N-OH-ABP
(Fig. 11), and N-OH-DMABP (Fig. 12) by the PAT and MAT isozymes from
rapid and slow acetylators were examined.
The PAT isozyme, derived from homozygous rapid acetylator
hamster liver cytosol, exhibited significantly higher levels of
AcCoA-dependent NAT and OAT activities, than the PAT isozyme derived
from homozygous slow acetylator (Table 3). In contrast, the MAT
isozymes showed similar levels of NAT and OAT activities in rapid
and slow acetylator hamster liver cytosol (Table 3). By comparison
the PAT and MAT isozymes, from both homozygous rapid and slow
acetylators, exhibited similar NAT activity towards INH (Fig. 13).
Apparent Maximum Velocities of NAT Activity in Homozvgous Rapid and
Slow Acetylator Hamster Liver Cytosol
AcCoA-dependent NAT activity was determined in crude liver
cytosol preparations from homozygous rapid acetylators and
Fig. 8. An ion-Exchange FPLC of PABA NAT Activity.
Acetyitransferase activity in nmoles/min/ml
is plotted on the left ordinate versus
fraction number on the abscissa for
AcCoA-dependent PABA NAT activity. The top
panel represents liver cytosol from a
homozygous rapid acetylator hamster (Bio.
87.20) and the lower panel represents liver
cytosol from a homozygous slow acetylator
hamster (Bio. 82.73/H). The right ordinate
indicates % KCI of the elutant. For further











































Fig. 9. An ion-Exchange FPLC of AF NAT Activity.
Acetyltransferase activity in nmoles/min/ml
is plotted on the ordinate versus fraction
number on the abscissa for AcCoA-dependent AF
NAT activity. The top panel represents liver
cytosol from a homozygous rapid acetylator
hamster and the lower panel represents liver
cytosol from a homozygous slow acetylator
hamster. The salt gradient is illustrated in





Fig. 10. Anion-Exchange FPLC of AcCoA-Dependent
Metabolic Activation of N-OH-AF Via OAT
Activity. Metabolic activation of N-OH-AF
in nmoles bound/15 min/mg DNA/ml is plotted
on the ordinate versus fraction number on
the abscissa. The top panel represents
liver cytosol from a homozygous rapid
acetylator hamster and the lower panel
represents liver cytosol from a homozygous
slow acetylator hamster. The salt gradient
is illustrated in Fig. 8. For further




































































































Fig. 11. An ion-Exchange FPLC of AcCoA-Dependent
Metabolic Activation of N-OH-ABP Via OAT
Activity. Metabolic activation of N-OH-ABP
in nmoles bound/15 min/mg DNA/ml is plotted
on the ordinate versus fraction number on
the abscissa. The top panel represents
liver cytosol from a homozygous rapid
acetylator hamster and the lower panel
represents liver cytosol from a homozygous
slow acetylator hamster. The salt gradient
is illustrated in Fig. 8. For further






































































Fig. 12. An ion-Exchange FPLC of AcCoA-Dependent
Metabolic Activation of N-OH-DMABP Via OAT
Activity. Metabolic activation of
N-OH-DMABP in nmoles bound/15 min/mg DNA/ml
is plotted on the ordinate versus fraction
number on the abscissa. The top panel
represents liver cytosol from a homozygous
rapid acetylator hamster and the lower
panel represents liver cytosol from a
homozygous slow acetylator hamster. The
salt gradient is illustrated in Fig. 8.

















































TABLE 3. Partial Purification of PAT and HAT Isozymes by Anton-Exchange FPLC Chromatography.






























































aTotal activity eluted ln PAT peak.
''Total activity eluted ln MAT peak.
cAcCoA-dependent reaction; units are moles acetylated/mln of NAT activity.
^AcCoA-dependent reaction; units are moles bound/15 mln/mg DNA.
eAcCoA-dependent reaction; units are moles bound/15 mln/ng DNA of OAT activity.
Fig. 13. Anion-Exchange FPLC of INH NAT Activity.
AcetyItransferase activity in nmoies/min/ml
is plotted on the ordinate versus fraction
number on the abscissa for AcCoA-dependent
INH NAT activity. The top panel represents
liver cytosol from a homozygous rapid
acetylator hamster and the lower panel
represents liver cytosol from a homozygous
slow acetylator hamster. The salt gradient
is illustrated in Fig. 8. For further












































homozygous slow acetylators. As shown in Table 4, the apparent Vmax
of NAT activity in homozygous rapid acetylator liver cytosol was
significantly higher (p < 0.01) than the apparent Vmax of NAT
activity of homozygous slow acetylator liver cytosol with varying
substrate concentrations of AcCoA (Fig. 14), PABA (Fig. 15), AF
(Fig. 16), and ABP (Fig. 17). In contrast, there was no significant
difference (p > 0.05) in the apparent Vmax of liver cytosol ic INH
NAT activity between the acetylator genotypes (Table 4, Fig. 18).
Apparent Maximum Velocities of Partially Purified NAT Isozymes in
Homozygous Rapid and Slow Acetylator Liver Cytosol
Homozygous rapid and slow acetylator hamster liver cytosol were
partially purified by an ion-exchange chromatography. The two forms
of NAT isozymes, designated as PAT and MAT, were isolated in both
rapid and slow acetylator liver cytosol. Both the PAT and the MAT
isozymes catalyzed the AcCoA-dependent N-acetylation of PABA, INH,
AF, and ABP. The apparent Vmax of the PAT isozyme in homozygous
rapid acetylators exhibited a 95- to 110-fold higher PABA NAT
activity with AcCoA (Fig. 14) and PABA (Fig. 15) as the variable
substrates than the PAT isozyme of homozygous slow acetylators.
Similarly, the apparent Vmax of NAT activity in the PAT isozyme of
homozygous rapid acetylators was 7- to 10-fold higher (Table 4) than
the PAT isozyme of homozygous slow acetylators with AF (Fig. 16) and
ABP (Fig. 17). In contrast, the apparent Vmax of NAT activity
catalyzed via the MAT isozyme did not exhibit a significant






































































Table values represent Mean + S.D. for three or more animals.
Apparent Vmi
acetylator.
* ax in RR acetylator genotype is significantly higher (P< 0.01) than rr
Fig. 14. Michaelis-Menten Kinetic Constants for
Hamster Liver NAT Activity. PABA NAT
activity in nmoles/min/mg is plotted on the
ordinates versus micromolar concentration
of AcCoA on the abscissae. The left panels
represent rapid acetylators (RR) and the
right panels represent homozygous slow
acetylators(rr). The top panels represent
determinations in unpurified cytosol, the
center panels represent determinations with
the polymorphic NAT isozyme (PAT) and the
lower panel represent determinations with
the monomorphic NAT isozyme (MAT). The
initial PABA concentrations was 0.44 mM for
each cytosol and 0.22 mM for each isozyme
determination. The inset figures illus
trate Eadie-Hofstee transformations of the
data. In some cases, the enzyme rate in
nmoIes/m i n/mg is pIotted as exponent i aI.
The kinetic constants derived from this
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Fig. 15. Michaelis-Menten Kinetic Constants for
Hamster Liver PABA NAT Activity. PABA NAT
activity in nmoles/min/mg is plotted on the
ordinates versus micromolar concentration
of PABA on the abscissae. The initial
concentration for AcCoA in each assay was
2.22 mM in cytosol and 1.0 mM for the two
NAT isozymes. The inset figures represent
Eadie-Hofstee transformations of the data.
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Fig. 16. Michaelis-Menten Kinetic Constants for
Hamster Liver AF NAT Activity. AF NAT
activity in nmoles/min/mg is plotted on the
ordinates versus micromolar concentration
of AF on the abscissae. The initial
concentration of AcCoA was 1.0 mM in all
assays. The inset figures represent
Eadie-Hofstee transformations of the data.








































































































































































Fig. 17. Michaelis-Menten Kinetic Constants for
Hamster Liver ABP NAT Activity. ABP NAT
activity in nmoles/min/mg is plotted on the
ordinates versus micromolar concentration
of ABP on the abscissae. The initial
concentration of AcCoA was 1.0 mM in all
assays. The inset figures represent
Eadie-Hofstee transformations of the data.
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Fig. 18. Michaelis-Menten Kinetic Constants for
Hamster Liver INH NAT Activity. INH NAT
activity in nmoles/min/mg is plotted on the
ordinates versus micromolar concentration
of INH on the abscissae. The initial
concentrations of AcCoA were 2.22 mM in
cytosol and 1.0 mM for the two NAT
isozymes. The inset figures represent
Eadie-Hofstee transformations of the data.













































































































































































































difference between acetylator genotypes for the N-acetylation of
PABA, AF, ABP, or INH (Table 4, Figs. 15-18).
Comparisons of kinetic constants of the PAT and MAT isozymes,
within the rapid acetylator genotype, revealed that the PAT isozyme
showed an 18- to 30-fold higher apparent Vmax in NAT activity
towards PABA (Fig. 15), AF (Fig. 16), and ABP (Fig. 17) than the MAT
isozyme (Table 4). On the other hand, comparison of the kinetic
constants of the PAT and MAT isozymes within the homozygous slow
acetylator genotype indicated that the MAT isozyme expressed a
7-fold higher apparent Vmax in PABA NAT activity than the PAT
isozyme (Fig. 15, Table 4). In contrast, the PAT isozyme showed a
higher apparent Vmax towards AF (Fig. 16) and ABP (Fig. 17) NAT
activities than the MAT isozyme in slow acetylators (Table 4). The
MAT isozyme showed a 2-fold higher apparent Vmax for INH NAT
activity than the PAT isozyme in both rapid and slow acetylators
(Fig. 18, Table 4).
Apparent Km Determinations of NAT Activity in Homozygous Rapid and
Slow Acetylator Liver Cytosol
M i chaeIi s-Menten k i net i c constants were der i ved for NAT act i v i ty
in homozygous rapid and slow acetylator hamster liver cytosol as
described in Materials and Methods. PABA NAT activity was measured
as a function of varying AcCoA concentrations to derive an apparent
Km for the AcCoA acetyl donor. The Km values were 931 and 256 uM
for homozygous rapid and slow acetylators, respectively. Under
these conditions, the apparent Km was 3.5-fold higher in the
homozygous rapid acetylator genotype than the homozygous slow (Fig.
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14, Table 5). The apparent Km towards PABA, INH, AF, and ABP were
determined in the presence of saturating levels of AcCoA. The
kinetic constants differed between substrates and genotypes. The
apparent Km for PABA was 8.5-fold lower in the homozygous rapid
acetylator genotype than the homozygous slow acetylator genotype
(Fig. 15, Table 5). In contrast, the apparent Km for INH, AF, and
ABP were similar, yet slightly higher in the homozygous rapid
acetylator genotype than the homozygous slow acetylator genotype
(Figs. 16-18, Table 5).
Apparent Km Determinations of Partially Purified NAT Isozymes in
Homozygous Rapid and Slow Acetylator Liver Cytosol
The apparent Km values of the PAT and MAT isozymes also differed
between substrates and acetylator genotypes. The apparent Km of the
PAT isozyme was significantly lower in the homozygous rapid
acetylator genotype than in the homozygous siow acetylator genotype
for PABA, whereas it was significantly higher for AF, ABP, and AcCoA
(Figs. 14-17, Table 5). The apparent Km of the MAT isozyme was
substantially lower (26-fold) in the homozygous rapid acetylator
genotype (Km = 81 uM) than in the homozygous slow (Km = 2120 uM) for
PABA, but it was significantly higher for AcCoA in the homozygous
rapid acetylator (Km = 436 uM) than in the homozygous slow
acetylator (Km =142 uM) (Figs. 14-15, Table 5). The apparent Km of
the MAT isozyme towards AF (Fig. 16), ABP (Fig 17), and INH (Fig.
18) did not differ significantly between the acetylator genotypes
(Table 5).





















































































Table values represent Mean +_ S.D. for three or more animals.
*Apparent Km in RR acetylator genotype is significantly different
(P < 0.05) than rr acetylator genotype.
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Purification of PAT and MAT Isozymes
Q-Sepharose anion-exchange chromatography was used to separate
the PAT and MAT isozymes from the liver cytosol of homozygous rapid
acetylator hamsters. Subsequently, the PAT and MAT isozymes were
further purified by sequential Sephacryl S-200 gel filtration and
an ion-exchange FPLC chromatography (Fig. 7). The data in Table 6
and Fig. 19 summarize a typical purification of hepatic PAT
isozyme. PAT activities were determined at each step with the
prototypic polymorphic substrate PABA (Table 6). The fold
purification factor was typically between 500- and 2400-fold and the
yield was about 2-10%.
Table 7 and Fig. 20 summarize the purification of the MAT
isozyme. The specific activity for the MAT isozyme was determined
at each purification step using PABA and INH as substrates. The
specific activity with PABA as the acetyI-acceptor was 7796 units/mg
of protein which represented only 4% of the catalysis rate for the
purified PAT isozyme. The specific activity with INH as the
acetyI-acceptor was 1764 units/mg of protein and represented a
150-fold purification with a 1.0% yield.
Protein Homogeneity and Molecular Weight Determinations
Native PAGE and SDS-PAGE were used to determine whether the PAT
and MAT isozymes were purified to homogeneity. The PAT sample
extracted from native PAGE exhibited high NAT activity (Fig. 21).
























































Initial concentrations In the reactions Mixture were 0.22 aM PABA and 1.00 aM AcCoA.
Fig. 19. Chromatographic Purification of PAT from
Homozygous Rapid Acetylator Hamster
Liver. Polymorphic PABA NAT activity in
nmoles/min/ml is plotted on the left
ordinate versus fraction number on the
abscissa. The top panel represents
Q-Sepharose an ion-exchange chromatography,
the center panel represents Sephacryl
S-200 gel filtration chromatography, and
the bottom panel represents an ion-exchange
FPLC chromatography. The right ordinate
indicates % KCI of the elutant. For




























































































































Fig. 20. Chrofflatographic Purification of MAT from
Homozygous Rapid Acetylator Hamster Liver.
Monomorphic INH NAT activity in nmoles/
min/ml is plotted on the ordinate versus
fraction number on the abscissa. The top
panel represents Q-Sepharose anion-exchange
chromatography, the center panel represents
Sephacryl S-200 gel filtration chroma
tography, and the bottom panel represents
an ion-exchange FPLC chromatography. The
right ordinate indicates % KCI of the

















































































Fig. 21. Native Gel Analysis of Purified PAT from
Homozygous Rapid Acetylator Hamster Liver.
The PAT Isozyme was applied to native PAGE
as described in Materials and Methods.
Following electrophoresis, gels were sliced
and the protein band was extracted and
assayed for PABA NAT activity. The NAT
activity in nmoIes/min/ml is plotted on the
ordinate versus gel slice number on the
abscissa. The specific activity of gel












































Following SDS-PAGE, a single protein band was detected after silver
staining (Fig. 22). In contrast, the MAT isozyme was not purified
to homogeneity using the procedure described in this study (data not
shown).
The molecular weight of the reduced PAT isozyme was estimated
from SDS-PAGE using standard proteins. An apparent molecular weight
of 37-38 KD was obtained for the PAT isozyme (Fig. 22).
Comparison of PAT and MAT Acetyl Transfer Reactions
Partially purified Sephacryl S-200 PAT and MAT isozymes of
homozygous rapid acetylator hamster liver cytosol were analyzed for
a diverse set of acetyl transfer reactions as shown in Table 8. The
relative specificity of the two isozymes to catalyze the various
acetyl transfer reactions appears to be substrate and
activity-dependent (Table 8). Most of the AcCoA-dependent
N-acetylation of PABA and AF, and the AcCoA-dependent O-acetylation
of N-OH-AF are catalyzed by the PAT isozyme. In striking contrast,
essentially all of the AcCoA-independent arylhydroxamic acid N,O-AT
activity for either N-OH-AAF or N-OH-AABP is catalyzed by the MAT
isozyme. These results substantiate studies done with more crude
preparations.
Heat Inactivation of NAT and OAT Activities
The heat inactivation rates of NAT and OAT activities in the PAT
and MAT isozymes of homozygous rapid acetylator hamsters were
determined to assess whether the PAT and MAT isozymes are single
Fig. 22. SDS-PAGE of Purified PAT from Homozgyous
Rapid Acetylator Hamster Liver. SDS-
polyacrylamide slab gels (12.5%) were
prepared and run as described under
Materials and Methods. Protein bands were
detected by silver stain. Lane 1 and 4
contain molecular weight markers as
described under Materials and Methods.
Lane 2 contains 16 ug of liver cytosol.














Table 8. Relative Capacity of Homozygous Rapid Acetylator Hamster Liver Cytosol PAT and MAT
Acetyltransferase Isozymes to Catalyze Various Acetyl Transfers*.
Acetyl Transfer










































aPAT and MAT isozyme partially purified through Sephacryl S-200
chromatography. Table values represent Mean + S.D. n - 3.
"Enzyme activity expressed as nmoles/min/mg protein.
cEnzyme activity expressed as pmoles bound/min/mg DNA/mg protein.
"An average of duplicate determinations from a single enzymatic preparation.
75
proteins capable of catalyzing both the NAT and OAT activities.
Partially purified Sephacryl S-200 PAT and MAT liver preparations
were used, as well as the purified PAT liver preparation obtained by
anion-exchange FPLC chromatography (Mono Q). PABA (1 mM), AF (2.5
mM), and N-OH-AF (5.0 mM) served as substrates. Thermal stability
was determined after preincubation at 55°C for various time points
(Figs. 23-24). The PAT and MAT heat inactivation rates followed
first order kinetics. The MAT heat inactivation rate constants of
PABA and AF NAT and N-OH-AF OAT activities did not differ
significantly (P > 0.05) (Table 9). The heat inactivation
half-lives were 4.46 min for PABA NAT activity, 4.38 min for AF NAT
activity, and 4.97 min for N-OH-AF OAT activity.
The partially purified Sephacryl S-200 PAT isozyme exhibited
similar heat inactivation rates for AF NAT and N-OH-AF OAT
activities; however, these rates differed significantly (P < 0.05)
from PABA NAT activity. Similar results were obtained upon further
purification of this isozyme on an ion-exchange chromatography FPLC
(Mono Q). The heat inactivation half-lives were 3.76 min for PABA
NAT activity, 1.99 min for AF NAT activity, and 2.25 min for N-OH-AF
OAT activity.
After pre incubation at 55°C for 5 min, a heated/control (H/C)
ratio was used to determine the remaining proportion of enzyme
activity. The H/C ratios for the NAT and OAT activities catalyzed
via the PAT and MAT isozymes are shown in Table 10. The results
suggested that PAT-catalyzed AF NAT and N-OH-AF OAT activities are
Fig. 23. Thermal Inactivation of the MAT Isozyme from
Homozygous Rapid Acetylator Hamster Liver.
Partially purified Sephacryl S-200 MAT
isozyme was analyzed for PABA NAT, AF NAT,
and N-OH-AF OAT activities following
incubations at 55°C for the times
indicated. The percent residual activity is
plotted on the ordinate versus time of
incubation at 55°C on the abscissa. The top
panel (A) represents PABA NAT activity, the
center panel (B) represents AF NAT activity,
and the lower panel (C) represents N-OH-AF
OAT activity. The inset figures represent

























Fig. 24. Thermal Inactivation of the PAT Isozyme from
Homozygous Rapid Acetylator Hamster.
Partially purified Sephacryl S-200 and the
homogenous poIymorph i c acety11 ransferase
isozyme were analyzed for PABA NAT, AF NAT,
and N-OH-AF OAT activities following
incubations at 55°C for the times
indicated. The percent residual activity is
plotted on the ordinate versus time of
incubation at 55°C on the abscissa. The
left panel represents Sephacryl S-200
partially purified PAT isozyme and the right
panel represents highly purified PAT
isozyme. The top panels (A and D) represent
PABA NAT activity, the center panels (B and
E) represent AF NAT activity), and the lower
panels (C and F) represent N-OH-AF OAT
activity. The inset figures represent
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Table 9. Thermal Stability of NAT and OAT Activities Catalyzed by Rapid Acetylator
Hamster Liver Isozymes.
Isozyme Preparation Thermal inactivation Rate Constant (Min"1)
PABA NAT AF NAT N-OH-AF OAT
MAT Sephacryl S-200a 0.155 ± 0.020c 0.159 _+ 0.29c 0.140 +_ 0.029c
PAT Sephacryl S-200a 0.185 +_ 0.012d 0.348 +. 0.071e 0.308 +_ 0.023e
PATf Mono Qb 0.152 +_ 0.028d 0.404 ± 0.100e 0.284 _+ 0.082e
Table values represent Mean ^ S.D. n - 3.
alsozyme partially purified through Sephacryl S-200 chromatography.
bIsozyme highly purified through anion-exchange FPLC chromatography.
cRate constants not significantly different (P > 0.05) for MAT isozyme.
dRate constants of PABA NAT significantly different from AF NAT and N-OH-AF OAT
(P < 0.05) for PAT isozyme.
eRate constants of AF NAT and N-OH-AF OAT not significantly different (P > 0.05).
fTable values obtained from a single assay.
Table 10. Thermal Inactivation Heated/Control Ratio of NAT and OAT Activities
Catalyzed by Rapid Acetylator Hamster Liver Isozymes.
Isozyme H/C Ratio
PABA NAT AF NAT N-OH-AF-OAT
MATa 0.463 ± 0.88 0.343 _+ 0.051 0.320 +_ 0.078 *
PAT 0.430 + 0.044b 0.257 + 0.021c 0.217 + 0.025c
The effects of preincubation at 55°C for 5 min on Sephacryl S-200 PAT and MAT
isozymes. Table values represent Mean _+ S.D. n = 3.
aH/C ratios not significantly different (P> 0.05) for MAT isozyme.
bH/C ratio of PABA NAT significantly different (P < 0.05) from AF NAT and
N-OH-AF OAT for PAT isozyme.
CH/C ratio of AF iNAT and N-OH-AF OAT not significantly different (P > 0.05).
80
more thermolabile than PABA NAT activity. The H/C ratios for the
various MAT acetyl transfer reactions, however, were not
significantly different (P > 0.05) (Table 10).
Determination of PAT Ami no Acid Sequence
Homogenous PAT samples were taken to the Microchemical
Facilities at Emory University (Atlanta, GA) for sequencing
analysis. Determination of protein sequence from their ami no
terminal by automatic Edman degradation was unsuccessful because the
N-terminal was blocked. Subsequent PAT samples have been subjected
to trypsin digestion. The tryptic peptides are presently being
isolated, and purified by HPLC for sequence analysis.
CHAPTER V
DISCUSSION
The acetylation polymorphism is a heritable trait of two alleles
at a single gene locus (Weber and Hein, 1985). Genetic variability
in acetylation capacity has been associated with differences in
susceptibility to aryIamine-induced carcinogenesis (Weber 1987; Hein
1988a). Several studies have demonstrated that metabolic activation
is a required factor for the initiation of aryIamine-induced
carcinogenesis. Acetylation reactions have been identified as key
metabolic steps in the activation/deactivation of aryIamine
carcinogens and their metabolites (Miller and Miller, 1981b).
AryIamine-induced bladder and colorectal carcinogenic models have
suggested that variability in the levels of NAT and OAT activities
are important factors in the genetic predisposition of individuals
to these cancers (Hein, 1988a). Consequently, animals which exhibit
the acetylation polymorphism are useful models for elucidating the
mechanism(s) involved in aryIamine-induced carcinogenesis.
The objective of this project was to investigate the genetic and
biochemical characteristics of AcCoA-dependent NAT and OAT cytosolic
enzymes with respect to genotype-dependent activity, kinetic
constants, and chromatographic properties utilizing inbred Syrian
hamsters of defined acetylator genotype.
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Arylamine NAT and N-hydroxyarylamine OAT activities exhibited a
similar pattern of acetylation polymorphism for the substrates
tested. An acetylator gene-dose relationship was observed for PABA,
AF, and ABP in hamster liver cytosol (Table 1). The highest levels
of NAT activity were expressed in homozygous rapid acetylator
hamsters and the lowest levels in homozygous slow acetylator
hamsters. These results indicate the existence of an acetylator
genotype-dependent expression of NAT activity in hamster liver.
Similar results have also been obtained with cytosol derived from
hamster bladder (Hein et al., 1987c), peripheral blood (Hein et al.,
1986b), intestine, kidney, and lung (Hein et al., 1987b), and colon
(Ogolla et al., 1988).
The magnitude of the difference in NAT activity between rapid
and slow acetylator genotypes was substrate-dependent with the
polymorphic PABA NAT activity in rapid acetylators about 82-fold
greater than in the slow acetylators, while AF and ABP were 7- and
5-fold higher, respectively (Table 1). In contrast, INH exhibited
similar levels of NAT activity across acetylator genotypes.
AcCoA-dependent metabolic activation of N-OH-AF in hamster liver
cytosol also showed an acetylation polymorphism (Table 2). Higher
activity was exhibited in homozygous rapid acetylators than in the
homozygous slow acetylators. An acetylator genotype-independent
expression was observed for the AcCoA-dependent metabolic activation
of N-OH-ABP and N-OH-DMABP in crude liver cytosol (Table 2). The
polymorphic expression of N-OH-AF and the monomorphic expression of
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N-OH-ABP and N-OH-DMABP illustrate the substrate-dependent
expression of the OAT polymorphism. The O-acetylation of
N-hydroxyarylamine substrates has also been reported in other
mammalian species including human liver, colon (Flammang and
Kadlubar, 1986; Flammang et al., 1987), and bladder (Kirlin et al.,
1989) cytosols. Human OAT-mediated metabolic activation of N-OH-AF
and N-OH-DMABP expressed in these tissues was acetylator
genotype-dependent. Unlike in humans, previous studies with liver
cytosol derived from rapid and slow acetylator inbred mice (Hein et
al., 1988) and the present hamster study demonstrated that the
metabolic activation of N-OH-DMABP exhibited acetylator
genotype-i ndependent express i on.
The expression of multiple forms of acetyltransferase activity
in hamster liver has been reported previously (Hein et a I., 1985b;
Smith and Hanna, 1986; Kato and Yamazoe, 1988). Partial
purification of hamster liver cytosol, by anion-exchange
chromatography indicated the presence of two distinct NAT isozymes
in each acetylator genotype. These isozymes differed in
chromatographic properties, substrate specificity, and genetic
control. The PAT isozyme(s) was acetylator genotype-dependent and
exhibited higher catalytic activity in rapid acetylators than in
slow acetylators for all substrates tested except INH (Figs. 8-10).
The MAT isozyme(s) was acetylator genotype-independent and exhibited
similar catalytic activity in rapid and slow acetylators (Figs.
8-10). Recently, Grant et al. (1989) also demonstrated the presence
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of two arylamine NATs in human liver cytosol. These NATs exhibited
indistinguishable molecular masses (31 KD); however, they could be
separated by an ion-exchange chromatography. In addition, they were
functionally distinguished by their difference in apparent
affinities for the acceptor amine sulfamethazine.
The present data indicates that both the PAT and NAT isozymes in
hamster liver cytosol catalyze the AcCoA-dependent N-acetylation of
arylamines and the O-acetylation of N-hydroxyarylamines (Figs. 8-13,
Table 3 and 8). Saito et al. (1986) reported the purification of a
single enzyme from the liver cytosol of outbred Syrian golden
hamsters. The molecular mass of the purified acetyItransferase was
estimated to be 33 KD by gel filtration and SDS-PAGE. The
acetyItransferase purified by Saito et al. (1986) appears to be the
same or similar to the MAT isozyme characterized in the present
study, since both enzymes exhibit high levels of N,O-AT activity.
In contrast, that purified enzyme appears to differ from the PAT
isozyme, since very low N,0-AT activity is exhibited by the latter
enzyme.
In comparison to crude cytosol, the PAT isozyme(s) exhibited
levels of AcCoA-dependent OAT and NAT activities that were
consistent with the acetylation polymorphism for all substrates
tested except INH (Table 3, Figs. 8-13). However, the MAT
isozyme(s) showed levels of OAT and NAT activities that did not vary
with acetylator genotype (Table 3, Figs. 8-13). These results
demonstrate that the levels of expression of both NAT and OAT
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activities are consistent with acetylator genotype as reflected by
the PAT isozyme.
To further characterize the NAT activities expressed in liver
cytosol and partially purified PAT and MAT isozymes,
Michaelis-Menten kinetic constants were determined using homozygous
rapid and slow acetylator hamster liver preparations.
In crude cytosol, the apparent Vmax for PABA, AF, and ABP NAT
activities were significantly higher in the rapid acetylator
genotype than the slow acetylator genotype. In contrast, the
apparent Vmax for INH NAT activity was similar across acetylator
genotypes (Table 4). These findings are consistent with the
polymorphic expression of PABA (Andres and Weber, 1986) and AF (Hein
et aI., 1982b) NAT activity reported in inbred rabbit liver cytosol,
but dissimilar to the polymorphic expression of INH NAT activity
observed in rabbit liver cytosol (Hein et aI., 1982c).
Determinations of the apparent Vmax catalytic activity of the
partially purified PAT and MAT isozymes of rapid and slow acetylator
genotypes clearly show that the PAT isozyme reflects the polymorphic
expression of the NAT activity. This suggests that the PAT isozyme
plays a significant role in the metabolism of arylamine
carcinogens. The cytosolic differences in NAT activity observed
between rapid and slow acetylators for the N-acetylation of PABA,
AF, and ABP are primarily due to the PAT isozyme(s). By comparison,
the lack of catalytic difference in cytosolic INH NAT activity
between rapid and slow acetylators is due to the MAT isozyme(s)
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(Table 4). Pat has been designated as the gene symbol for the PAT
locus in the hamster, with Patr representing the rapid acetylator
allele and Pats representing the slow acetylator allele (Hein,
1988b). The results of this investigation support the existence of
a single gene locus in hamster liver which regulates the PAT
isozyme(s). This isozyme(s) exhibits genetic variability in the
N-acetylation of arylamine and in the O-acetylation of
N-hydroxyaryIamine carcinogens (Tables 3-5). However, the MAT
isozyme(s) shows levels of NAT and OAT activities that do not vary
with acetylator genotype.
The NAT activity of crude cytosol and of the partially purified
PAT and MAT isozymes was further characterized by determination of
the apparent Km for various substrates. The relationship between
acetylator genotype and apparent Km values was substrate dependent.
The apparent Km of cytosolic NAT activity was higher in homozygous
rapid than in homozygous slow acetylators for all substrates tested,
except PABA (Table 5). This result is consistent with similar
reports in inbred rabbit liver cytosol (Andres and Weber, 1986),
inbred hamster bladder cytosol (Yerokun et a I., 1989) and human
liver cytosol (Kilbane et a I., 1988). The apparent Km for AcCoA in
rapid and slow acetylator hamster liver cytosol (Table 5) is
consistent with observations in rabbits (Reeves et al., 1988). The
physiological basis for the relatively low affinity of NAT for its
endogenous co-factor AcCoA is not known. However, recent studies by
Kato and Yamazoe (1988) and the present study suggest that
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relatively high levels of AcCoA concentrations are required for the
N-acetylation reaction jn vitro. In addition, jn vivo studies in
humans and isolated rat liver cells have demonstrated that an
increase in the cellular concentration of AcCoA, via ethanol
induction, increases the acetylation of drugs (01 sen and Moriand,
1978; 1982). Therefore, AcCoA concentration appears to be a rate-
limiting factor in the acetylation reaction jn vivo. The present
findings are also consistent with recent studies by Grant et al.
(1989). They isolated and purified two NATs from human liver
cytosol which differed in their affinity for AcCoA. It is
interesting that the apparent Kms observed for the PAT and MAT
isozymes of homozygous rapid acetyiator are higher than those in the
slow acetyiator hamster. At present, this can not be accounted for;
however, the data from the crude cytosol repeatedly indicated that
the rapid acetyiator exhibited a lower affinity for the co-factor
than the slow acetyiator (Table 5).
The apparent Km of the PAT isozyme differed significantly
between homozygous rapid and slow acetylators for each substrate
tested (Table 5). In contrast, the apparent Km for the MAT isozyme
for AF and ABP did not differ, suggesting that the MAT isozyme(s)
catalyzing the N-acetylation of these carcinogens is the same or
very similar in homozygous rapid and slow acetylators.
The apparent Km values for PABA were lower in homozygous rapid
than slow acetylators in crude cytosol and in both the PAT and MAT
isozymes. The apparent Km for PABA was particularly high in slow
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acetylator cytosol and in the slow acetylator MAT isozyme. This
observation suggest that the N-acetylation of PABA occurs almost
exclusively via the PAT isozyme.
Kinetic characterization of the partially purified NAT isozymes
provide evidence for an intrinsic structural difference between the
PAT and MAT isozymes in both rapid and slow acetylators. The
kinetic data also suggests that rapid and slow acetylators express
structural variants of the PAT isozyme (Patr and Pats allozymes)
rather than quantitative differences in a single PAT isozyme.
However, the purification of the Pats allozyme needs to be
accomplished to strengthen this conclusion. Furthermore, the data
indicate that the MAT isozymes are not expressed as structural
variants in rapid and slow acetylators. Thus, the results support
the hypothesis that there exists at least two isozymes of NAT in
hamster liver cytosol, the PAT isozyme which is poIymorphica11y
regulated by the acetylator gene locus Pat and the MAT isozyme which
may be monomorphically regulated, yielding catalytically similar NAT
isozymes in rapid and slow acetylators.
To fully elucidate the biochemical mechanism(s) of the PAT and
MAT isozymes and determine whether the NAT, OAT, and N,O-AT
activities reside on the same protein, the purification of these
isozymes is required. It is of special interest to determine the
following: the definitive number of NAT isozymes; the precise
differences in ami no acid sequence between the PAT allozymes; and
the nature of the gene mutation responsible for the existence of
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structurally variant Pat1" and Pats allozymes. It is expected that
the cloning and analysis of cDNA and genomic DNA encoding the PAT
allozymes will provide this information. Consequently, it is of the
utmost importance to purify the NAT isozymes. A combination of gel
f iItrat i on and an i on-exchange chromatograph i c procedures were
employed to purify the PAT and MAT isozymes from the 105,000 x g
supernatant of homozygous rapid acetylator hamster liver
homogenate. The PAT isozyme was purified to apparent homogeneity as
demonstrated by SDS-PAGE after silver staining. However, the MAT
isozyme was not purified to apparent homogeneity under the same
conditions. It is expected that slight modifications of the present
procedure, coupled with a 4-aminoazobenzene Sepharose 6-B affinity
chromatography step, will achieve the purification of the MAT
i sozyme. The 4-am i noazobenzene Ii gand exh i b i ts a strong b i nd i ng to
the MAT isozyme (Smith and Hanna, 1986). The MAT isozyme from
hamster liver has been purified to electrophoretic homogeneity by
Saito et al. (1986). The highly purified MAT isozyme catalyzes the
AcCoA-dependent arylamine N-acetylation and N-hydroxyarylamine
0-acetylation, as well as the AcCoA-independent arylhydroxamic acid
N,0-acyI transfer.
The PAT and MAT isozymes are capable of catalyzing several
acetyl transfer reactions (Table 8). The relative specificity of
the two isozymes appear to be reaction- and substrate-dependent.
Most of the AcCoA-dependent NAT and OAT activities are eluted with
the PAT isozyme. These activities could not be separated by protein
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purification techniques which detect differences in ionic charge and
molecular size. As shown in Table 8, the PAT/MAT ratios clearly
indicate that the PAT isozyme plays an important role in the
acetylator genotype-dependent expression of both NAT and OAT
activities. In contrast, the PAT isozyme exhibited little or no
AcCoA-independent N,0-AT activity. The similarities between NAT and
OAT activities do not necessarily mean that both activities are
catalyzed by the same protein. However, the results of this
investigation strongly support the existence of a PAT isozyme which
is under the genetic control of the acetylator gene and catalyzes
both the NAT and OAT activities. The MAT isozyme catalyzes the
AcCoA-dependent NAT and OAT activities, as well as the
AcCoA-independent N,0-AT activity. MAT plays the predominant role
in the expression of the N,0-AT activity and appears to be
independent of the acetylator gene locus.
Studies in outbred hamster (Saito et a I., 1986) and inbred mouse
(Mattano et a I., 1989) liver cytosols have indicated the
purification of a single enzyme capable of catalyzing the
N-acetylation of aryIamines, the 0-acetylation of
N-hydroxyaryIamines, and the N,0-acyI transfer of arylhydroxamic
acids. It is possible that the enzyme purified by Saito et al.,
(1986) and Mattano et al. (1989) is analogous to the MAT isozyme
isolated in this study.
One of the most commonly measured properties of enzymes in
biochemical genetics is thermal stability (WeinshiI bourn, 1981).
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Differences in thermal stability is a sensitive indicator of
variation in enzyme structure (Paigen, 1971; Campbell et a I.,
1986). The physical basis of variation in protein thermal stability
is a subject of controversy (Stellwagen and Wilgus, 1978). The
sensitivity of thermal inactivation, as a test for structural
changes, is illustrated by the findings on carboxypeptidase A. Two
forms of this enzyme differ only in the antepenultimate C-terminal
ami no acid residue. One form with leucine in this position is twice
as labile as the other with valine (Walsh et al., 1966). Therefore,
variation in thermal stability is a potentially useful method for
the detection of protein structural differences. In addition, the
enzyme activity remaining after the heat inactivation treatment
divided by the basal enzyme activity is used to calculate a
so-called "heated/control" or "H/C" ratio. This ratio serves as a
measure of the thermal stability for an enzyme (WeinshiI bourn, 1981;
Campbell et al., 1986).
The heat inactivation rate constants of the partially purified
MAT isozyme towards each of the substrates tested (Table 9, Fig. 23)
exhibited no significant differences (P > 0.05). Furthermore, the
H/C ratios for the MAT isozyme towards the various substrates tested
exhibited similar degrees of thermostabiIity. The data suggest that
the NAT, OAT, and N,0-AT activities are carried out by the same MAT
isozyme in hamster liver cytosol.
The heat inactivation rate constants of AF NAT and N-OH-AF OAT
activities catalyzed by PAT were very similar, suggesting that the
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same or a very similar enzyme catalyzes the N-acetylation of AF and
the 0-acetyIation of N-OH-AF. However, these rates differed from
that obtained with PABA NAT. This observation suggests that the
active site of the PAT isozyme distinguishes between the structural
configuration of PABA and that of AF and N-OH-AF carcinogens. The
PAT isozyme has a higher affinity for PABA than AF. Consequently,
the PABA molecule may force the PAT isozyme into its maximal active
form at a faster kinetic rate and with less steric hindrance than AF
and N-OH-AF. It may be possible that the interaction between PABA
and the PAT isozyme is different from that of AF and N-OH-AF. This
may account for the resulting difference in the heat inactivation
rate constants between PABA and the carcinogens (AF, N-OH-AF).
Alternatively, PABA NAT is catalyzed by a distinct enzyme that is
also regulated by acetylator genotype. Further research is
required to fully understand the heat inactivation rate differences
between the arylamine drug PABA, and the arylamine and
N-hydroxyarylamine carcinogens AF and N-OH-AF.
Although the regulation of the N-acetylation polymorphism at the
enzymatic level has been well studied, the molecular mechanism(s)
that control the acetylation polymorphism have not been elucidated.
It is not certain whether the different PAT allozymes originate from
different alleles or from the post-transcriptional or
post-translational processing of a single gene. Several questions
regarding the expression of genetic information can only be answered
after the detection and isolation of a gene-specific messenger RNA.
93
In order to elucidate the molecular basis that controls the
acetylation polymorphism, it is essential to understand the
structure, function, and regulation of the acetylator gene(s) and
its product(s).
This project has provided some direction towards the elucidation
of the molecular mechanism(s) that regulate the acetylation
polymorphism. The purified Pat1* allozyme could be used to develop
monoclonal antibodies. These monoclonal antibodies could be used as
probes for the isolation of a cDNA clone encoding the Pat1"
allozyme. If monoclonal antibodies are not available, the Patr
allozyme amino acid sequence could be used to synthesize 32P-labeled
ol igonucleotides. These oligonucleotides could serve as a probe to
screen a cDNA library to identify a cDNA clone encoding the Patr
allozyme and a genomic library to isolate the acetylator gene(s).
Susceptibility to aryIamine-induced careinogenesis has been
associated with the enzyme system acetyltransferase(s) which
metabolizes aryI amine carcinogens into ultimate carcinogenic species
that bind to DNA. The PAT isozyme, isolated and purified in this
project, plays an important role in the biotransformation of
aryIamines and their N-hydroxyarylamine metabolites. The results of
this investigation strongly support the existence of structural
variant Patr and Pats allozymes. The precise differences in ami no
acid sequence between the Pat allozymes and the nature of the gene
mutation are currently under investigation in our laboratory.
CHAPTER VI
SUMMARY AND CONCLUSIONS
The relationship between acetylator genotype and the occurrence
of bladder and colorectal cancer in humans has generated increased
interest in the genetic and biochemical basis responsible for this
relationship. The present investigation revealed that
AcCoA-dependent arylamine NAT and N-hydroxyarylamine OAT activities
are genetically co-regulated by an acetylator gene. Two distinct
forms of NAT were identified in hamster liver and designated as PAT
and MAT. Biochemical and kinetic characterization studies revealed
functional and structural differences between the PAT and MAT
isozymes in both rapid and slow acetylators. Furthermore, the
kinetic data suggested that the PAT isozyme is expressed as
structural variant allozymes regulated by the acetylator gene locus
(Pat). The PAT isozyme of rapid acetylators was purified to
apparent homogeneity. The purified protein catalyzes both the
N-acetylation of arylamine and the O-acetylation of
N-hydroxyarylamine carcinogens but little or no N,0-acyI transfer of
arylhydroxamic acids. The conclusions from this investigation
follow:
1. The expression of arylamine NAT and N-hydroxyarylamine OAT
activities are regulated by acetylator genotype. However, the




2. The acetylator genotype-dependent expression of NAT and OAT
activities in hamster liver cytosol is reaction- and substrate-
dependent .
3. Partial purification of inbred hamster liver cytosol by
an ion-exchange chromatography reveals the presence of two distinct
forms of NAT activity. Both forms of the enzyme are expressed in
homozygous rapid and slow acetylators. One form of the enzyme is
termed PAT because its expression is acetylator genotype-dependent
whereas, the other form is termed MAT because its expression is
acetylator genotype-independent.
4. Michaelis-Menten kinetic determinations reveal that the PAT
isozyme exhibits variations in apparent Km and Vmax towards the
arylamine carcinogens whereas, the MAT isozyme does not show
genotype-related variations in apparent Km and Vmax. This suggests
that the PAT aIlozymes are structural variants.
5. The PAT isozyme catalyzes the N-acetylation of aryIamines
and the O-acetylation of N-hydroxyaryIamines at catalytic levels
which are consistent with the acetylation polymorphism.
6. The MAT isozyme catalyzes the NAT, OAT, and N.O-AT
activities at catalytic levels which are acetylator
genotype-i ndependent.
7. The acetylator genotype-dependent expression of NAT activity
in hamster liver cytosol towards arylamine carcinogens is
attributable to structural variants (aIlozymes e.g., enzymes encoded
via the Pat1" and Pats alleles) of the PAT isozyme.
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8. The acetyI at ion of arylamine and N-hydroxyarylamine
carcinogens is catalyzed by a common acetyItransferase isozyme in
hamster liver regulated by the acetylator gene (Pat).
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